摘要
目的观察培美曲塞单药或联合卡铂治疗晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。方法 43例Ⅲ~Ⅳ期NSCLC的患者均经病理组织学或细胞学检查确诊。培美曲塞单药或联合卡铂治疗后评价疗效。结果 43例患者均可评价疗效,10例部分缓解PR,24例稳定SD,疾病控制率（DCR）79.10%（34/43）。最主要的毒性反应为粒细胞减少,可耐受。结论培美曲塞单药或联合卡铂治疗晚期非小细胞肺癌NSCLC有较好疗效,毒性反应轻,易耐受。
Objective To evaluate the clinical and toxicity of pemetrexed in treating advanced non-small cell lung cancer（NSCLC）.Methods Forty three patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study.After treatment of pemetrexed plus carboplatin,the curative effect was evaluated.Results Partical remission（PR） was found in 10 cases.The diseases control rate（DCR） was 79.10%（34/43）.The main side effects were leucopenia,and it was tolerable.Conclusions Pemetrexed is effective,safe and well tolerable in the treatment of advanced NSCLC.
出处
《医药论坛杂志》
2011年第8期69-71,共3页
Journal of Medical Forum
关键词
培美曲塞
非小细胞肺癌
卡铂
Pemetrexed
Non-small cell lung cancer
Carboplatin
